Latest Mass Tort News and Updates

On September 29, the first bellwether case in Bard hernia mesh lawsuits will go before the federal jury for which the U.S. District Judge has outlined the pretrial and…

AndroGel maker AbbVie, won the verdict in the third bellwether case as the jury found that the testosterone replacement therapy maker was not…

Nexium: MDL No. 2757; in re: Proton-pump inhibitor Products liability litigation, created in August 2017, presided by Judge Claire C. Cecchi, in the U.S. District of New Jersey. Other…

A metal-on-metal hip litigation, centralized since May 2017 and involving at least 200 Smith & Nephew Birmingham lawsuits, is witnessing a steady inflow of product liability cases. Recently, a lawsuit was filed by a Minnesota man in the U.S.…

A group of plaintiffs has filed a class action lawsuit against Johnson & Johnson for not updating the Talcum Powder label to warn the consumers, especially women…

Gauging filing Short Form Complaint would not suffice to handle the wave of expected PPI lawsuits, Co-Lead Counsel for the plaintiffs filed a proposed case management order (PDF), requesting temporary clubbing of at least 300 plaintiffs…

During the closing arguments of a Mesothelioma lawsuit, the counsel representing defendants Johnson & Johnson and its talc supplier, Imerys Talc America Inc., and Cyprus Amax Minerals Co., an Imerys predecessor, stated that the…

A lawsuit was filed against Johnson & Johnson, Imerys Talc America, and Personal Care Products Council in the U.S. District Court for the District of Massachusetts by a woman from Massachusetts, who alleges that the long-term use of…

The fifth bellwether trial in the multidistrict litigation (MDL) over AbbVie Inc.'s testosterone replacement therapy (TRT) drug AndroGel, saw Illinois Federal Jury supporting the defendant. During the trial that began on May 7, 2018, a…

AndexXa, the only antidote for Factor Xa blood thinner, approved by the U.S. Food and Drug Administration(FDA) on May 4 to reverse uncontrollable bleeding problems, will be initially available in only those 40 to 50 hospitals where the…